SCHEMBL4871941

SCHEMBL4871941

Cc1cc2c(=O)n3nc(C)cc3c(=O)n2n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.41
PARP1 P09874 1/20 0.41
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TSHR P16473 2/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
TP53 P04637 1/20 0.32
ALOX15 P16050 1/20 0.32
SLC11A2 P49281 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22729817 0.78 PARP1 (0.34) CYP1A2PARP1KDM4EALDH1A1HPGD
SCHEMBL31309174 0.66 PARP1 (0.39) CYP1A2PARP1KDM4EALDH1A1HPGD
SCHEMBL7913110 0.66 NPC1 (0.47) CYP1A2PARP1KDM4EALDH1A1HPGD
SCHEMBL14341735 0.65 KDM4E (0.37) CYP1A2PARP1KDM4EALDH1A1HPGD
SCHEMBL15382212 0.65 ALDH1A1 (0.33) KDM4EALDH1A1LMNAKMT2A
SCHEMBL14341744 0.64 KDM4E (0.40) CYP1A2PARP1KDM4EALDH1A1HPGD
SCHEMBL16081467 0.63 SMN1; SMN2 (0.41) KDM4EALDH1A1HPGDTSHRLMNA
SCHEMBL16738968 0.62 KDM4E (0.46) CYP1A2PARP1KDM4EALDH1A1HPGD
SCHEMBL4244986 0.61 USP2 (0.45) CYP1A2PARP1KDM4EALDH1A1HPGD
SCHEMBL545028 0.61 KDM4E (0.50) CYP1A2PARP1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4005100-A ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. (US) 1977-01-25 US claimed
WO-2023212219-A1 TRICYCLIC PARP1 INHIBITORS AND USES THEREOF XINTHERA, INC. (US) 2023-11-02 WO disclosed
US-20080090836-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation BIOLIPOX AB (SE) 2008-04-17 US disclosed
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation BIOLIPOX AB (SE) 2007-09-27 US disclosed
US-4005100-A ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. (US) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation ALOX15, ALOX15B, ALOX12 CYP1A2 38/4885PARP1 2047/4885KDM4E 3533/4885
US-20080090836-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation ALOX15, ALOX15B, ALOX12 CYP1A2 50/4885PARP1 1606/4885KDM4E 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.